melagatran has been researched along with Coronary Thrombosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drouet, L | 1 |
| Falk, E; Hansson, GK; Hemdahl, AL; Thorén, P | 1 |
| Chen, L; Gustafsson, D; Mattsson, C; Mehta, JL; Nichols, WW; Saldeen, TG | 1 |
| Abrahamsson, T; Björkman, JA; Hendriks, D; Leurs, J; Mattsson, C; Nerme, V; Scharpé, S; Schatteman, K | 1 |
1 review(s) available for melagatran and Coronary Thrombosis
| Article | Year |
|---|---|
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Topics: Administration, Oral; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Thrombosis; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Hirudin Therapy; Humans; Orthopedics; Polysaccharides; Prodrugs; Prothrombin; Research; Thrombin; Thromboembolism; Time Factors; Venous Thrombosis | 2003 |
3 other study(ies) available for melagatran and Coronary Thrombosis
| Article | Year |
|---|---|
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Topics: Animals; Apolipoproteins E; Azetidines; Benzylamines; Biomarkers; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptors, LDL; Thrombin; Troponin T | 2004 |
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Azetidines; Benzylamines; Coronary Thrombosis; Dogs; Electric Stimulation; Fibrinogen; Fibrinolytic Agents; Glycine; Microscopy, Electron, Scanning; Partial Thromboplastin Time; Thrombin | 1998 |
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Topics: Animals; Aorta; Azetidines; Benzylamines; Carboxypeptidase B2; Coronary Circulation; Coronary Thrombosis; Dogs; Enzyme Activation; Enzyme Precursors; Female; Fibrinolytic Agents; Glycine; Male; Models, Animal; Random Allocation; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Veins | 2002 |